Allogeneic haematopoietic stem cell transplantation for adult T‐lymphoblastic lymphoma: A real‐world multicentre analysis in China
British Journal of Haematology · 2024-06 · 204 (6) · 2390-2399
DOI: 10.1111/bjh.19481 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 25.04.2024. Verfasst von Wenxuan Huo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Ce…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Tongzhou District Distinguished Young Scholars, Shanghai Municipal Health Commission Project of Disciplines of Excellence, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
In this multicentre, real‐world study, we aimed to identify the clinical outcomes and safety of allogeneic haematopoietic stem cell transplantation (allo‐HSCT) in T‐lymphoblastic lymphoma (T‐LBL). A total of 130 Ann Arbor stage III or IV T‐LBL patients (>16 years) treated with allo‐HSCT across five transplant centres were enrolled. The 2‐year cumulative incidence of disease progression, the probabilities of progression‐free survival (PFS), overall survival (OS) and non‐relapse mortality (NRM) after allo‐HSCT were 21.0%, 69.8%, 79.5% and 9.2% respectively. Patients with central nervous system (CNS) involvement had a higher cumulative incidence of disease progression compared with those without CNS involvement (57.1% vs. 18.9%, HR 3.78, p = 0.014). Patients receiving allo‐HSCT in non‐remission (NR) had a poorer PFS compared with those receiving allo‐HSCT in complete remission (CR) or partial remission (49.2% vs. 72.7%, HR 2.21, p = 0.041). Particularly for patients with bone marrow involvement and achieving CR before allo‐HSCT, measurable residual disease (MRD) positivity before allo‐HSCT was associated with a poorer PFS compared with MRD negativity (62.7% vs. 86.8%, HR 1.94, p = 0.036). On multivariate analysis, CNS involvement at diagnosis and receiving allo‐HSCT in NR were associated with disease progression. Thus, our real‐world data suggested that allo‐HSCT appeared to be an effective therapy for adult T‐LBL patients with Ann Arbor stage III or IV disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, Chin…
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation C…
- Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
ORCID-Profile: Wenxuan Huo, Xiaoyu Zhu, Xiaojin Wu, Xiaoxia Hu
Förderung
- Tongzhou District Distinguished Young Scholars
- Shanghai Municipal Health Commission Project of Disciplines of Excellence
- CAMS Innovation Fund for Medical Sciences
- Peking University People's Hospital Research and Development Funds
- Natural Science Foundation of Beijing Municipality
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Huo, W., Gao, L., Song, K., Huang, J., Wang, N., Cao, L., Liu, Y., Wang, F., Li, C., Zhu, X., Wu, X., Cao, Y., Mo, X., & Hu, X. (2024). Allogeneic haematopoietic stem cell transplantation for adult T‐lymphoblastic lymphoma: A real‐world multicentre analysis in China. British Journal of Haematology, 204(6), 2390-2399. https://doi.org/10.1111/bjh.19481
Vancouver
Huo W, Gao L, Song K, Huang J, Wang N, Cao L, et al. Allogeneic haematopoietic stem cell transplantation for adult T‐lymphoblastic lymphoma: A real‐world multicentre analysis in China. British Journal of Haematology. 2024;204(6):2390-2399. doi:10.1111/bjh.19481
BibTeX
@article{Huo2024,
author = {Huo, Wenxuan and Gao, Lu and Song, Kaidi and Huang, Jiayu and Wang, Na and Cao, Leqing and Liu, Yang and Wang, Fengrong and Li, Chuan and Zhu, Xiaoyu and Wu, Xiaojin and Cao, Yang and Mo, Xiaodong and Hu, Xiaoxia},
title = {Allogeneic haematopoietic stem cell transplantation for adult T‐lymphoblastic lymphoma: A real‐world multicentre analysis in China},
journal = {British Journal of Haematology},
year = {2024},
volume = {204},
number = {6},
pages = {2390--2399},
doi = {10.1111/bjh.19481}
}
EUVIMED